| 1  | TITLE PAGE   |
|----|--|
| 2  |  |
| 3  | DEVELOPMENT AND VALIDATION OF A PREDICTION RULE FOR BENEFIT AND  |
| 4  | HARM OF ORAL ANTICOAGULATION IN NON-VALVULAR ATRIAL FIBRILLATION   |
| 5  |  |
| 6  | Sergio Raposeiras-Roubin <sup>1,2</sup> , Tze-Fan Chao <sup>3</sup> , Emad Abu-Assi <sup>1,2</sup> , Yi-Hsin Chan <sup>4</sup> ,   |
| 7  | Inmaculada González Bermúdez <sup>1,2</sup> , Jo-Nan Liao <sup>3</sup> , Ling Kuo <sup>3</sup> , Rocío González  |
| 8  | Ferreiro <sup>1,2</sup> , Andrés Íñiguez-Romo <sup>1,2</sup>   |
| 9  |  |
| 10 | (1) Cardiology Department. University Hospital Álvaro Cunqueiro, Vigo, Spain.  |
| 11 | (2) Instituto de Investigación Sanitaria Galicia Sur. Vigo, Spain.   |
| 10 | (2) Division of Cardiology Donartment of Medicine, Tainei Veterana Coneral Hospital  |
| 12 | (3) Division of Cardiology, Department of Medicine, Taiper Veterans General Hospital   |
| 13 | and Cardiovascular Research Center, National Yang Ming Chiao Tung University,  |
| 14 | Taipei, Taiwan   |
| 15 | (4) The Cardiovascular Department, Chang Gung Memorial Hospital and College of   |
| 16 | Medicine, Chang Gung University, Taoyuan, Taiwan   |
| 17 |  |
| 18 | TOTAL WORD COUNT: 4370 words   |
| 19 | FUNDING: None  |
| 20 | DISCLOSURES: We declare no conflict of interest.   |
| 21 |  |
| 22 | Address for correspondence:  |
| 23 | Sergio Raposeiras Roubín   |
| 24 | Cardiology Department. Hospital Álvaro Cunqueiro.  |
| 25 | Estrada de Clara Campoamor, 341, 36213 Vigo, Pontevedra, Spain.  |
| 26 | Phone: 0034620170387. Fax number: 0034986811111.   |
| 27 | https://orcid.org/0000-0002-6462-4715  |
| 28 | NOTE: This preprint reports new research that has not been and should not be used to set the set of |

### 29 ABSTRACT

30

Background. Oral anticoagulation therapy (OAC) remains the gold standard for 31 stroke prevention in patients with atrial fibrillation (AF). In real life, there are patients who do 32 not receive OAC due to high bleeding risk. In those patients, left atrial appendage closure 33 (LAAC) has emerged as a potential alternative for stroke prevention. With this study, we 34 aimed to develop a clinical decision tool to identify patients expected to derive harm vs 35 benefit from OAC therapy. 36 37 **Methods.** Among 14,915 AF patients with CHA2DS2-VASc  $\geq$  1 (2 for women) from CardioCHUVI-AF registry (78% with OAC), a prediction rule was derived using a linear 38 regression model to predict the stroke-bleeding balance. This rule was externally validated in 39 the Taiwan AF registry, with 26,595 patients (70.5% with non OAC therapy). 40 41 Results. A simplified risk score was created using 7 clinical variables. The low-score 42 group ( $\leq$  -8 points) was associated with higher rates of bleeding than stroke (7.25 vs 1.11 and 3.27 vs 2.58 per 100 patients/year in derivation and validation cohorts, respectively; p<0.001). 43 In those patients, OAC was harmful. In contrast, high-score group ( $\geq$  +6 points) was 44 45 associated with higher stroke risk than bleeding risk (2.32 vs 1.71 and 4.19 vs 1.64 per 100 patients/year in derivation and validation cohorts, respectively; p<0.001), with great benefit of 46 OAC therapy. 47

48 **Conclusions.** A prediction rule balancing stroke and bleeding risks correctly identify 49 patients with harm vs benefit from OAC therapy. This rule requires further prospective 50 evaluation to assess potential effects on patient care to select candidates for LAAC.

51

| 52 | <u>KEYWORDS</u>  |
|----|--|
| 53 |  |
| 54 | Atrial fibrillation; Bleeding; Ischemic Stroke; Oral Anticoagulation; Score. |
| 55 |  |
| 56 |  |
| 57 |  |
| 58 |  |
| 59 |  |
| 60 |  |
| 61 |  |
| 62 |  |
| 63 |  |
| 64 |  |
| 65 |  |
| 66 |  |
| 67 |  |
| 68 |  |
| 69 |  |
| 70 |  |
| 71 |  |

| 72             | CLINICAL PERSPECTIVE   |
|----------------|--|
| 73             |  |
| 74             | What is new?   |
| 75<br>76<br>77 | <ul> <li>We developed and externally validated a simple user-friendly clinical tool -OAC score- to balance both embolic and bleeding risks in atrial fibrillation patients with CHA2DS2-VASC ≥1 (excluding female sex).</li> </ul> |
| 78<br>79       | • According to OAC score, we can identify atrial fibrillation patients expected to derive benefit vs harm from anticoagulation therapy.  |
| 80<br>81       | • Patients with a low OAC score have much higher rates of bleeding than stroke, which is exaggerated with anticoagulation. The opposite occurs in patients with a high score.  |
| 82<br>83       | What are the clinical implications?  |
| 84<br>85<br>86 | • A standardised stratification of both stroke and bleeding risk in atrial fibrillation patients at high embolic risk can be performed using an user-friendly, comprehensive tool (the OAC score).                                 |
| 87<br>88<br>89 | • In patients with low risk OAC score, despite high risk CHA2DS2-VASC, anticoagulation is not beneficial and left atrial appendage closure could be an alternative.  |
| 90<br>91<br>92 | • Further studies are needed to assess the impact of oral anticoagulation and left atrial appendage closure in patients with atrial fibrillation according to the OAC score risk groups.   |
| 93             |  |

| 94  | ABBREVIATIONS                       |
|-----|-------------------------------------|
| 95  |                                     |
| 96  | AF: Atrial Fibrillation             |
| 97  | CKD: Chronic Kidney Disease         |
| 98  | HCM: Hypertrophic Cardiomyopathy    |
| 99  | IS: Ischemic Stroke                 |
| 100 | LAAC: Left Atrial Appendage Closure |
| 101 | MB: Major Bleeding                  |
| 102 | OAC: Oral Anticoagulation           |
| 103 |                                     |
| 104 |                                     |
| 105 |                                     |
| 106 |                                     |
| 107 |                                     |
| 108 |                                     |
| 109 |                                     |
| 110 |                                     |
| 111 |                                     |
| 112 |                                     |
| 113 |                                     |

114

### TEXT

### 115 INTRODUCTION

The CHA<sub>2</sub>DS<sub>2</sub>-VASc score has a great clinical impact to select patients with atrial fibrillation 116 (AF) at high embolic risk in order to establish the indication for oral anticoagulation 117 Use of OAC in patients with  $\geq 1$  non-sex CHA<sub>2</sub>DS<sub>2</sub>-VASc risk factor 118 (OAC)(1, 2). significantly reduces the chances of thromboembolic cardiovascular events, such as stroke, 119 120 and mortality in AF patients(3). However, the clinical benefit of anticoagulant treatment is offset by the risk of bleeding. Data from the PREFER-AF(4), GARDFIELD-AF(5), and 121 NCDR-PINNACLE(6) studies, show that 20%, 30%, and 40% of the patients with AF and a 122 CHA<sub>2</sub>DS<sub>2</sub>-VASc score  $\geq$ 2 are not treated with OAC, respectively. A perceived increased 123 bleeding risk is the most frequent reason for withholding OAC for embolic prevention in non-124 valvular AF(7). Although guidelines recommend the use of bleeding risk scores -e. g. HAS-125 BLED-, those scores do not determine OAC prescription; they only help to identify 126 127 potentially reversible bleeding risk factors in order to correct them(8).

Due to an overlap of risk factors for bleeding and stroke, patients with AF are more usually at 128 an increased bleeding risk (9). Decision-making regarding anticoagulation can be particularly 129 130 challenging in these patients, especially when both stroke and bleeding risks are high. Left atrial appendage closure (LAAC) could be a reasonable option for those patients, especially 131 when the expected risk associated with OAC is greater than the expected benefit (10). To 132 guide clinical decision-making for patients at high risk of stroke and AF, we designed this 133 study focused on identifying factors that predict whether the expected increase in MB 134 associated with OAC would outweigh the expected benefit of reduced IS for individual 135 patients. Those factors will be used to develop a decision tool to help select AF patients 136 without net benefit from OAC who are candidates for LAAC. 137

## 138 METHODS

Study population. A retrospective registry-based cohort study including all consecutive 139 patients (n=16,202) with a diagnosis of AF between January 2014 and January 2018 in the 140 141 health area of Vigo (Galicia, Spain) was used (CardioCHUVI-AF registry; ClinicalTrials.gov identifier: NCT04364516)(11). Patients were identified through administrative databases at 142 both the hospital and ambulatory level, using the regional electronic healthcare records 143 system. Electronic medical records were reviewed in all patients, and diagnosis of AF was 144 145 confirmed by a compatible electrocardiogram. Clinical, laboratory, and therapeutic data were collected using an encoded database. Patients with missing baseline and follow-up data were 146 147 excluded (n=146), together with those with valvular AF (moderate-severe mitral stenosis or mechanical prothesis valve; n=350). Patients without none non-sex CHA<sub>2</sub>DS<sub>2</sub>-VASc risk 148 factor (n=791) were also excluded. Therefore, the final cohort comprised 14,915 AF patients 149 with  $CHA_2DS_2$ -VASc  $\geq 1$  for men and  $\geq 2$  for women. The study was conducted in 150 accordance with the principles of the Declaration of Helsinki and was approved by the local 151 152 ethics committee (Autonomous Committee of Research Ethics of Galicia, code HAC-ACO-2018-01, registry 2018/258). 153

Study Goals. The goal of this study was to identify clinical variables that determine whether 154 a patient's bleeding risk is lower or higher than the embolic risk, in order to distinguish 155 156 patients who can derive the greatest benefit from those who can experience the most harm from OAC therapy. Considering individual patient characteristics and their independent 157 associations with Ischemic Stroke (IS) and Major Bleeding (MB), this study sought to stratify 158 159 outcomes based on a single multivariable risk score. This entailed (1) identifying factors 160 associated with IS and MB, (2) choosing those that selectively predicted either IS or MB to generate a simplified risk score, and (3) assessing the OAC therapy results observed in the 161 registry, stratified by the new risk score. An ideal score would identify patients with 162

simultaneous high stroke risk (and corresponding high benefit with OAC therapy) and low bleeding risk (and corresponding low risk of harm with OAC therapy), and vice versa. In addition, the ability of the score to balance both IS and MB risks within an external sample was assessed, using the Taiwan AF registry with 26,595 patients with AF and  $CHA_2DS_2$ -VASc score  $\geq 1$  for men or  $\geq 2$  for women.

Embolic and Bleeding End Points. The primary embolic end point was IS (as defined by the 168 Standardized Data Collection for CV Trials Initiative and the US Food and Drug 169 170 Administration)(12), and the primary bleeding end point was MB (as defined by the International Society on Thrombosis and Haemostasis)(13). During the follow-up, two data 171 managers independently reviewed the clinical history of each patient to identify possible 172 173 events. All suspected events were independently reviewed by 2 specialists in the clinically relevant areas of cardiology and internal medicine. Both data managers and specialists 174 underwent a study-specific training on event definitions and the adjudication process. Finally, 175 an independent clinical events committee revised and adjudicated all events. 176

# 177 Statistical Analysis

Development of Stroke and Bleeding Risk Models. Clinical characteristics were compared 178 between patients experiencing events during follow-up and those without events, using Fisher 179 exact or t tests as appropriate. Cox regression was used to develop 2 separate models: the first 180 to predict IS and the second to predict MB. Data were censored at the time of IS or MB, or at 181 182 the time of death, change in OAC therapy status, or last known contact, whichever was earliest. A total of 40 candidate variables potentially associated with IS or MBs based on a 183 comprehensive literature review and clinical plausibility were identified (Table 1). Candidate 184 variables that differed in bivariable comparisons at a significance level  $\leq 0.150$  were 185 incorporated. Stepwise selection was then performed, using the 0.050 significance level. To 186 identify possible heterogeneous treatment effects, simple Cox regression models were 187

developed for each outcome including treatment group, variable of interest, and their interaction term. Interactions terms significant at a P value  $\leq 0.100$  were entered into the stepwise selection process with other candidate variables. Proportionality was evaluated for all variables in the models. Model discrimination was assessed using Harrell's c-statistic, and calibration with the Gronnesby and Borgan goodness-of-fit test.

Development of a Simplified Clinical Prediction Score. For each patient, the predicted risks 193 (cumulative incidence) of IS and MB were estimated, assuming OAC therapy and separately 194 195 assuming non-OAC therapy. The difference between these 2 predicted values represented the predicted balance between IS and MB. A linear regression model was created, using the 196 predicted balance between IS and MB -as the outcome- and all predictors that were selected 197 198 in the stroke and bleeding models. Baseline variables that statistically accounted for more 199 than 1% of the observed variation in estimated balance between IS and MB were included in a simplified clinical prediction score, called OAC score. All variables were assigned an integer 200 201 score of 1 or 2 (or -1 to -2) based on  $\beta$  coefficients. The range of potential scores was

between -22 and 10. Clinically relevant score groupings were created, defining patients more

203 likely to be harmed from OAC (low score group) vs those more likely to benefit (moderate-204 high score groups). Low score was defined as percentile 10 of patients with negative OAC 205 score values (i.e. a score  $\leq$  - 8), and high score as percentile 90 of patients with positive OAC 206 score values (i.e. a score  $\geq$  6). Kaplan-Meier event rates were compared by score groups, and 207 absolute risk differences in IS and MB rates across score groups were assessed. Statistical 208 analyses were conducted using *STATA* software, version 15 (Stata Corp, College Station, 209 Texas, USA).

210

211

### 212 **RESULTS**

213 **Derivation cohort.** A total of 14,915 patients with AF and  $CHA_2DS_2$ -VASc  $\geq 1$  for men or  $\geq 2$  for women were included in this analysis (derivation cohort). Of these, 11,632 patients 214 (78.0%) receiving OAC (86.8% VKA, 13.2% DOAC). During a mean follow up of 4.0 years 215 (IQR 2.4-5.7 years), 801 patients developed IS (1.3 per 100 patients/year) and 1,247 patients 216 developed MB (2.1 per 100 patients/year). Patients who had an IS during follow-up were 217 older, more likely women, had higher rates of prior stroke, aortic stenosis, hypertrophic 218 cardiomyopathy (HCM), chronic kidney disease (CKD), history of cancer and dementia, and 219 were less likely to have been treated with OAC compared with patients without an IS (Table 220 221 1). Patients with a MB were also older, more likely men, had a higher prevalence of smoking, enolism, and diabetes, had a higher prevalence of cardiovascular disease (including prior heart 222 failure and valvular heart disease), higher comorbidity (including dementia, malnutrition, 223 liver disease, CKD, anemia, trombopenia and prior bleeding admission), and were more likely 224 to have treated with OAC, corticosteroids and NSAIDs compared with patients without a MB 225 (Table 1). 226

227 Risk Prediction Models. In multivariable Cox regression (Table 2), significant predictors of both IS and MB included age, aortic stenosis, dementia, and permanent AF. Variables that 228 predicted only the risk of IS included prior stroke and HCM. Male sex, smoking, diabetes 229 230 mellitus, mitral regurgitation, CKD, liver disease, anemia, prior bleeding admission, prior gastrointestinal ulcer, malnutrition, and corticosteroid/NSAID use were significant 231 independent predictors of MB, but not of IS. Both models had moderate discrimination (c 232 233 statistic 0.687 and 0.671 for stroke and bleeding models, respectively), and were well calibrated (goodness-of-fit P = 0.116 and 0.549 for stroke and bleeding models, respectively). 234

Clinical Prediction Score. A simplified risk score –called OAC score– was created using 7
clinical variables (age, sex, prior stroke, prior bleeding, anemia, renal function, and liver

function) that were independently associated with more than 1% of the variation in the 237 238 balance between IS and MB in a linear regression model (Supplementary Table 1). The score, ranging from -22 to 10, assigned points as follows: for patients younger than 60 years, 0 239 points; for age 60 to 69,+1; for age 70 to 79,+2; for age 80 to 89,+3; for patients 90 years or 240 older,+4; for female sex, +3; for prior stroke, +4; for CKD stage 5, -11; for non-cirrhotic liver 241 disease (ALT or AST > 3 USL), - 6 points; for cirrhotic liver disease, -10 points; for 242 hemoglobin 10 to 11.9 g/dL, -5 points; for hemoglobin lower than 10 g/dL, -9 points; for prior 243 bleeding admission, -4 points. Patients were classified in 3 risk groups according to OAC 244 score: low ( $\leq$  - 8 points; n=242, 1.6%), moderate (from -8 to +6 points; n=11,264, 75.5%), 245 and high score ( $\geq$  + 6 points; n=3,409, 22.9%). The low-score group was associated with the 246 highest rates of MB and the most negative balance between IS and MB, whereas the opposite 247 occurred in the high-score group (Figure 1). Kaplan Meier curves for MB and IS according 248 the 3 risk groups are showed in Figure 2A and 2B. The impact of OAC therapy in stroke-249 bleeding balance is shown in Figure 3A. 250

External validation of OAC score. OAC score was validated in a Nationwide Cohort Study 251 from Taiwan, using the National Health Insurance Research Database in Taiwan(14). Among 252 253 the patients of Taiwan AF registry with CHA2DS2-VASc  $\geq 1$  (2 for women), data of OAC score were available in 26,595 patients. From them, only 29.5% were treated with OAC 254 255 therapy. OAC risk score was independently associated with the balance of embolichemorrhagic risk (Figure 4). According to the OAC score, 19.7%, 74.0%, and 6.3% of 256 257 patients are classified as low, moderate, and high score. A high OAC score is associated with more IS whereas a low OAC risk score is associated with more MB (Figures 5A and 5B). 258 259 Only patients with a low OAC risk score had a negative embolic-hemorrhagic balance, that 260 was exaggerated in anticoagulated patients (Figure 3B).

261

# 262 **DISCUSSION**

This study developed and validated a clinical prediction score based on embolic and bleeding risk factors to help physicians to identify AF patients with greater expected harm vs greater expected benefit from OAC therapy. Despite prior evidence suggesting that embolic and bleeding risk are strongly correlated, our results suggest that it may be possible to identify individual patients with discordant embolic risks and bleeding risks.

268 In patients with a low OAC score (i.e,  $\leq$  -8 points), the risk of bleeding events was clearly higher than the risk of embolic events in both the derivation cohort (78.0% with OAC 269 therapy) and the validation cohort (70.5% without OAC therapy). This finding was 270 exaggerated in anticoagulated patients. This is very interesting, because we can identify a 271 group of patients in who the benefit of OAC therapy against embolism is compromised by the 272 increased bleeding risk. In those patients, an alternative strategy should be sought, like 273 LAAC. A meta-analysis of 2 randomized clinical trials (PROTECT AF and PREVAIL) 274 comparing LAAC vs anticoagulation with vitamin K antagonists (VKA) in 2,406 patients at 275 276 high risk for stroke and increased risk of bleeding, showed a significant reduction of almost 50% in nonprocedural bleeding (15). In turn, LAAC was associated with similar rates of 277 nonprocedural stroke, and resulted in improved rates of hemorrhagic stroke and 278 cardiovascular/unexplained death. Recently, data from PRAGUE-17 showed that among 279 patients at high risk for stroke and increased risk of bleeding, LAAC vs direct oral 280 281 anticoagulants (DOACs) did not increase the rate of stroke (HR 1.00, 95% CI 0.40-2.51; p=0.99), whereas showed a trend to decrease the rate of nonprocedural bleeding (HR 0.53, 282 95%CI 0.26-1.06; p=0.07) (10). Current guidelines state that LAAC may be considered in AF 283 patients with contra-indications for long-term OAC therapy. However, with the results of 284 PROTECT-AF, PREVAIL and PRAGUE-17, it seems reasonable to take a step forward and 285

recommend it in those patients in whom the bleeding risk clearly exceeds the embolic risk. In 286 287 this sense, the OAC score can be very useful for clinicians, helping to the incorporation of transcatheter LAAC into a stroke prevention strategy for patients with an expected excess 288 bleeding rate. OAC score considers the balance between two key elements: the long-term 289 risks of thromboembolic events and the longer-term risk of bleeding. However, for derivation 290 to LAAC, another key element should be considered: the short-term procedure risk of 291 292 LAAC(16). With that in mind, the risk benefit of an invasive procedure such as LAAC must be balanced against the longer-term issues of continued exposure to anticoagulation and 293 bleeding(17). 294

Other therapeutic option to prevent stroke in patients with high bleeding risk could be Factor 295 296 XIa (FXIa) inhibitors. Whether FXIa inhibitors can play a role in this clinical scenario is 297 currently a pending challenge. FXIa inhibition represents a promising strategy to reduce stroke risk while preserving a patient's ability to clot when bleeding(18). The recent 298 299 PACIFIC-AF trial showed that asundexian -a FXIa inhibitor- resulted in lower rates of bleeding compared with apixaban in patients with AF, with similar embolic protection(19). 300 301 These data support the potential role for FXIa inhibition in patients with AF and make this strategy a promising avenue pending the results of future studies. 302

On the other hand, a high OAC score identifies patients with a very high embolic risk that markedly exceeds the expected risk of bleeding events, both in anticoagulated and nonanticoagulated patients –an aspect that is fulfilled in both derivation and validation cohorts–. In those patients there is a clear benefit of anticoagulation, and even indefinite OAC with LAAC could be useful, giving in consideration that the left atrial appendage is responsible for >90% of embolic strokes(20). Although a targeted approach to exclude this chamber combined with OAC therapy can be beneficial in those patients at very high embolic risk(21),

careful consideration of LAAC warrants an individualized discussion between physician andpatient.

312 Limitations. A number of limitations should be considered in interpreting these findings. As in any observational cohort study, our findings may reflect some degree of residual 313 confounding. First, as it is not a randomized clinical trial, there is a clear selection bias when 314 deciding to prescribe OAC. Therefore, these data could only be used to evaluate whether the 315 316 score stratified patients according to the balance between embolic and bleeding risk, and not 317 actual benefit or harm with OAC therapy. The usefulness of the OAC score to support clinical decision on the prescription of OAC therapy or LAAC should be regarded as hypothesis 318 generating at this stage and dedicated randomized trials should be carried out to evaluate the 319 320 validity of this potential application of the OAC score. Second, variables in the predictive 321 score included patient characteristics that have demonstrated an association with either embolic or bleeding events in prior studies. However, common predictive factors for both 322 323 embolic and bleeding risks were not included in the predictive score because these factors did not help identify discordant bleeding and embolic risks. The incorporation of more variables 324 into the individual bleeding and embolic models may have improved discrimination, at the 325 expense of parsimony. In addition, the estimation of risks based on the use of the separate 326 embolic and bleeding model coefficients rather than use of the simplified score could improve 327 328 the ability to predict such events and provide the opportunity for clinicians to identify patients with concordantly high embolic and bleeding risks, in addition to those with discordant risks. 329 However, we have searched for a simple and user-friendly score that has clinical implications 330 331 and widespread use. Third, although there remains a sizable proportion of patients, the patients used to derive the OAC score make up a group of patients -most of them 332 anticoagulated- that may not be representative of those seen in clinical practice. However, 333 validation was performed in a different population of AF patients -most of them non-334

| 335 | anticoagulated- with concordant results. Despite our optimism, use of this prediction score       |
|-----|---|
| 336 | should be cautious until further validation is performed in clinical trials, and optimal clinical |
| 337 | and procedural care to reduce overall bleeding and ischemic risks should be practiced             |
| 338 | independent of a patient's score.   |
| 339 | In conclusion, we have developed and tested the OAC score, a user-friendly tool to balance        |
| 340 | bleeding and embolic risks in AF patients. OAC score is feasible and effective with               |
| 341 | potentially important implications on the selection of patients for LAAC.                         |
| 342 |   |
| 343 |   |
| 344 |   |
| 345 |   |
| 346 |   |
| 347 |   |
| 348 |   |
| 349 |   |
| 350 |   |
| 351 |   |
| 352 |   |
| 353 |   |
| 254 |   |
| 554 |   |
| 355 |   |
| 356 |   |

| 357 |  |
|-----|--|
| 358 |  |
| 359 | Contributors.  |
| 360 | • SRR, TFC, EAA, and AIR conceived and designed the study.                                   |
| 361 | • IGF, RGF, YHC, JNL, and LK a did the analysis.   |
| 362 | • SRR, EAA and TFC drafted the manuscript.   |
| 363 | • All authors revised and approved the final version of the manuscript.                      |
| 364 | • SRR and EAA had full access to all of the data in the study and take responsibility for    |
| 365 | the integrity of the data and the accuracy of the data analysis.                             |
| 366 |  |
| 367 | Declaration of interest.   |
| 368 | • SRR has received honoraria for presentations and advisory boards from Amgen,               |
| 369 | Abbott, Sanofi, AstraZeneca, Daichii, Pfyzer-BMS, Bayer, and Boehringer.                     |
| 370 | • The rest of authors declare no competing interests.  |
| 371 |  |
| 372 | Founding source  |
| 373 | • The electronic registry was funded in a unconditioned way by Daiichi Sankyo, Pfyzer-       |
| 374 | BMS, Bayer and Boehringer Ingelheim.   |
| 375 |  |
| 376 | Acknowledgment   |
| 377 | • None.  |
| 378 |  |
| 379 | Data sharing.  |
| 380 | • Due to different data-sharing policies of the two datasets included in this study, not all |
| 381 | of which provided free access to data, data included in this study will not be made          |

available. Requests for the data from each included dataset should be made to thecorresponding author of each single registry.

384

### **REFERENCES**

385

 Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. *Eur Heart J.* 2021;42(5):373-498.

January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the
 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A
 Report of the American College of Cardiology/American Heart Association Task Force on
 Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society
 of Thoracic Surgeons. *Circulation*. 2019;140(2):e125-e51.

Lip GYH, Banerjee A, Boriani G, et al. Antithrombotic Therapy for Atrial Fibrillation:
 CHEST Guideline and Expert Panel Report. *Chest.* 2018;154(5):1121-201.

4. Kirchhof P, Ammentorp B, Darius H, et al. Management of atrial fibrillation in seven
European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation:
primary results of the PREvention oF thromboemolic events--European Registry in Atrial
Fibrillation (PREFER in AF). *Europace*. 2014;16(1):6-14.

Martin A, Siegal D, Verbrugge F, et al. Why do clinicians withhold anticoagulation in
patients with atrial fibrillation and CHA2DS2-VASc score≥2? *Arch Card Dis Suppl.*2019;11(1):83-4.

406 6. Lubitz SA, Khurshid S, Weng LC, et al. Predictors of oral anticoagulant non407 prescription in patients with atrial fibrillation and elevated stroke risk. *Am Heart J*.
408 2018;200:24-31.

Piazza G, Hurwitz S, Carroll B, Goldhaber SZ. Patients with perceived high-bleeding
risk and computerized decision support for stroke prevention in atrial fibrillation: an AFALERT substudy : Piazza: outcomes of high-bleeding risk AF patients. *J Thromb Thrombolysis*. 2021;52(1):281-90.

413 8. Edmiston MK, Lewis WR. Bleeding Risk Scores in Atrial Fibrillation: Helpful or
414 Harmful? *JAHA*. 2018;7(18):e010582.

9. Raposeiras-Roubín S, Abu-Assi E, Cespón Fernández M, et al. Trade-off between the
effects of embolic versus bleeding events on mortality in elderly patients with atrial
fibrillation. *Rev Esp Cardiol (Engl Ed)*. 2022;75(4):334-42.

418 10. Osmancik P, Herman D, Neuzil P, et al. Left Atrial Appendage Closure Versus Direct
419 Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation. *J Am Coll Cardiol.*420 2020;75(25):3122-35.

11. Raposeiras-Roubin S, Abu-Assi E, Marchán A, et al. Validation of Embolic and
Bleeding Risk Scores in Patients With Atrial Fibrillation and Cancer. *Am J Cardiol.*2022;180:44-51.

Hicks KA, Mahaffey KW, Mehran R, et al. 2017 Cardiovascular and Stroke Endpoint
Definitions for Clinical Trials. *Circulation*. 2018;137(9):961-72.

Schulman S, Angerås U, Bergqvist D, Eriksson B, Lassen MR, Fisher W. Definition
of major bleeding in clinical investigations of antihemostatic medicinal products in surgical
patients. *J Thromb Haemost.* 2010;8(1):202-4.

| 429 | 14. Chao TF, Liu CJ, Wang KL, et al. Should atrial fibrillation patients with 1 additional |
|-----|--|
| 430 | risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation? J Am      |
| 431 | Coll Cardiol. 2015;65(7):635-42.   |

Holmes DR, Jr., Doshi SK, Kar S, et al. Left Atrial Appendage Closure as an
Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation: A Patient-Level MetaAnalysis. *J Am Coll Cardiol.* 2015;65(24):2614-23.

435 16. Murtaza G, Boda U, Turagam MK, et al. Risks and Benefits of Removal of the Left
436 Atrial Appendage. *Curr Cardiol Rep.* 2020;22(11):129.

Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial
appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation:
a randomised non-inferiority trial. *Lancet*. 2009;374(9689):534-42.

Liuzzo G, Patrono C. A novel inhibitor of Factor XIa as potential haemostasis-sparing
anticoagulant for patients with atrial fibrillation. *Eur Heart J.* 2022;43(25):2354-5.

Piccini JP, Caso V, Connolly SJ, et al. Safety of the oral factor XIa inhibitor
asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a
multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. *Lancet*.
2022;399(10333):1383-90.

20. Collado FMS, Buchwald CMLv, Anderson CK, et al. Left Atrial Appendage
Occlusion for Stroke Prevention in Nonvalvular Atrial Fibrillation. *JAHA*.
2021;10(21):e022274.

449 21. Freixa X, Cruz-González I, Regueiro A, et al. Left Atrial Appendage Occlusion as
450 Adjunctive Therapy to Anticoagulation for Stroke Recurrence. *J Invasive Cardiol.*451 2019;31(8):212-6.

452

453

454

455

456

# **TABLES**

457 Table 1. Baseline characteristics of patients with vs without ischemic stroke or major

458 bleeding during the follow-up in the derivation cohort (n = 14,915)

|                                 | Ischemic stroke, No. (%) |                     |         | Major bleeding, No. (%) |               |         |
|---------------------------------|--------------------------|---------------------|---------|-------------------------|---------------|---------|
|                                 | Event                    | No Event            | Р       | Event                   | No Event      | Р       |
| Measure                         | ( <b>n=801</b> )         | ( <b>n=14,114</b> ) | Value   | (n=1,247)               | (n=13,668)    | Value   |
| Demographic                     |                          |                     |         |                         |               |         |
| Age, men (SD)                   | 79.8 (8.7)               | 77.0 (9.5)          | < 0.001 | 77.1 (8.4)              | 77.2 (9.6)    | 0.769   |
| Age, groups                     |                          |                     | < 0.001 |                         |               | < 0.001 |
| <60                             | 23 (2.9)                 | 711 (5.0)           |         | 35 (2.8)                | 699 (5.1)     |         |
| 60-69.9                         | 77 (9.6)                 | 2,420 (17.1)        |         | 215 (17.2)              | 2,282 (16.7)  |         |
| 70-79.9                         | 259 (32.3)               | 4,935 (35.0)        |         | 508 (40.7)              | 4,686 (34.3)  |         |
| 80-89.9                         | 367 (45.8)               | 5,237 (37.1)        |         | 403 (32.3)              | 5,201 (38.1)  |         |
| >=90                            | 75 (9.4)                 | 811 (5.7)           |         | 86 (6.9)                | 800 (5.9)     |         |
| Women                           | 471 (57.9)               | 7,528 (50.6)        | < 0.001 | 539 (42.6)              | 7,460 (51.7)  | < 0.001 |
| Overweight/obesity              | 677 (84.5)               | 11,932 (84.5)       | 0.987   | 1,061 (85.1)            | 11,548 (84.5) | 0.578   |
| Medical history                 |                          |                     |         |                         |               |         |
| Cigarette smoker                | 34 (4.2)                 | 595 (4.2)           | 0.968   | 74 (5.9)                | 555 (4.1)     | 0.002   |
| Alcohol abuse <sup>a</sup>      | 129 (16.1)               | 2,578 (18.3)        | 0.123   | 291 (23.3)              | 2,416 (17.7)  | < 0.001 |
| Hypertension                    | 596 (74.4)               | 10,669 (75.6)       | 0.448   | 931 (74.7)              | 10,334 (75.6) | 0.456   |
| Dyslipemia                      | 385 (48.1)               | 6,896 (48.9)        | 0.662   | 612 (49.1)              | 6,669 (48.8)  | 0.848   |
| Diabetes mellitus               | 172 (21.5)               | 2,847 (20.2)        | 0.372   | 303 (24.3)              | 2,716 (19.9)  | < 0.001 |
| Peripheral artery disease       | 35 (4.4)                 | 522 (3.7)           | 0.330   | 54 (4.3)                | 503 (3.7)     | 0.246   |
| Prior stroke                    | 95 (11.9)                | 899 (6.4)           | < 0.001 | 75 (6.0)                | 919 (6.7)     | 0.336   |
| Coronary artery disease         | 91 (11.4)                | 1,544 (10.9)        | 0.710   | 156 (12.5)              | 1,479 (10.8)  | 0.068   |
| Prior heart failure             | 76 (9.5)                 | 1,196 (8.5)         | 0.317   | 125 (10.0)              | 1,147 (8.4)   | 0.048   |
| $LVEF \le 40\%$                 | 46 (5.9)                 | 771 (5.7)           | 0.807   | 72 (5.9)                | 745 (5.7)     | 0.680   |
| Moderate-severe aortic stenosis | 42 (5.2)                 | 511 (3.6)           | 0.018   | 78 (6.3)                | 475 (3.5)     | < 0.001 |
| Moderate-severe MR              | 30 (3.7)                 | 479 (3.4)           | 0.594   | 60 (4.8)                | 449 (3.3)     | 0.004   |
| Bioprothesis                    | 13 (1.6)                 | 146 (1.0)           | 0.115   | 22 (1.8)                | 137 (1.0)     | 0.012   |
| HCM                             | 15 (1.9)                 | 169 (1.2)           | 0.092   | 20 (1.6)                | 164 (1.2)     | 0.216   |
| Pacemaker                       | 43 (5.4)                 | 727 (5.2)           | 0.787   | 84 (6.7)                | 686 (5.0)     | 0.009   |
| COPD                            | 86 (10.7)                | 1,641 (11.6)        | 0.444   | 144 (11.5)              | 1,583 (11.6)  | 0.971   |
| Kidney disease <sup>b</sup>     |                          |                     | 0.009   |                         |               | < 0.001 |
| Stage 1                         | 94 (11.7)                | 2,267 (16.1)        |         | 186 (14.9)              | 2,175 (15.9)  |         |
| Stage 2                         | 440 (54.9)               | 7,674 (54.4)        |         | 640 (51.3)              | 7,474 (54.7)  |         |
| Stage 3a                        | 147 (18.4)               | 2,392 (16.9)        |         | 228 (18.3)              | 2,311 (16.9)  |         |
| Stage 3b                        | 93 (11.6)                | 1,282 (9.1)         |         | 123 (9.9)               | 1,252 (9.2)   |         |
| Stage 4                         | 23 (2.9)                 | 418 (3.0)           |         | 52 (4.2)                | 389 (2.8)     |         |
| Stage 5                         | 4 (0.5)                  | 81 (0.6)            |         | 18 (1.4)                | 67 (0.5)      |         |

| Liver disease <sup>c</sup>   |                 |                     | 0.281       |                                   |                  | < 0.001 |  |  |  |
|--|-----------------|---------------------|-------------|-----------------------------------|------------------|---------|--|--|--|
| Mild liver disease   | 10 (1.2)        | 279 (2.0)           |             | 45 (3.6)                          | 244 (1.8)        |         |  |  |  |
| Cirrhosis  | 7 (0.9)         | 157 (1.1)           |             | 31 (2.5)                          | 133 (1.0)        |         |  |  |  |
| Anemia <sup>d</sup>  |                 |                     | 0.948       |                                   |                  | < 0.001 |  |  |  |
| Mild   | 102 (12.7)      | 1,798 (12.7)        |             | 221 (17.7)                        | 1,679 (12.3)     |         |  |  |  |
| Moderate-severe  | 19 (2.4)        | 361 (2.4)           |             | 63 (5.1)                          | 317 (2.3)        |         |  |  |  |
| Thrombopenia <sup>e</sup>  |                 |                     | 0.127       |                                   |                  | 0.002   |  |  |  |
| Mild   | 68 (8.5)        | 1,496 (10.6)        |             | 158 (12.7)                        | 1,406 (10.3)     |         |  |  |  |
| Moderate-severe  | 7 (0.9)         | 159 (1.1)           |             | 22 (1.8)                          | 144 (1.1)        |         |  |  |  |
| Prior bleeding admission   | 44 (5.5)        | 751 (5.3)           | 0.833       | 100 (8.0)                         | 695 (5.1)        | < 0.001 |  |  |  |
| History of GI ulcer  | 10 (1.2)        | 139 (1.0)           | 0.466       | 19 (1.5)                          | 130 (1.0)        | 0.052   |  |  |  |
| Corticosteroid/NSAID use   | 122 (15.3)      | 2,425 (17.2)        | 0.158       | 241 (19.3)                        | 2,306 (16.9)     | 0.028   |  |  |  |
| History of past cancer <sup>f</sup>  | 34 (4.2)        | 1,092 (7.3)         | 0.001       | 100 (7.9)                         | 1,026 (7.1)      | 0.294   |  |  |  |
| Active cancer <sup>f</sup>   | 11 (1.4)        | 317 (2.2)           | 0.101       | 31 (2.5)                          | 297 (2.2)        | 0.463   |  |  |  |
| Prior radiotherapy   | 11 (1.4)        | 319 (2.3)           | 0.097       | 34 (2.7)                          | 296 (2.2)        | 0.193   |  |  |  |
| Prior chemotherapy   | 8 (1.0)         | 214 (1.5)           | 0.239       | 15 (1.2)                          | 207 (1.5)        | 0.389   |  |  |  |
| Cognitive impairment <sup>g</sup>  | 101 (12.6)      | 1,117 (7.9)         | < 0.001     | 139 (11.1)                        | 1,079 (7.9)      | < 0.001 |  |  |  |
| Parkinson disease  | 16 (2.0)        | 248 (1.8)           | 0.616       | 27 (2.2)                          | 237 (1.7)        | 0.269   |  |  |  |
| Moderate-severe malnutrition <sup>h</sup>  | 48 (6.0)        | 733 (5.2)           | 0.323       | 92 (7.4)                          | 689 (5.0)        | 0.001   |  |  |  |
| AF type and management   |                 | × /                 |             | × /                               | × /              |         |  |  |  |
| AF type  |                 |                     | < 0.001     |                                   |                  | < 0.001 |  |  |  |
| Paroxysmal   | 114 (14.2)      | 2,379 (16.9)        |             | 160 (13.0)                        | 2,333(17.1)      |         |  |  |  |
| Persistent   | 96 (12.0)       | 3,068 (21.7)        |             | 239 (19.5)                        | 2,925 (21.4)     |         |  |  |  |
| Permanent  | 591 (73.8)      | 8,667 (61.4)        |             | 848 (67.5)                        | 8,410 (61.5)     |         |  |  |  |
| CHA <sub>2</sub> DS <sub>2</sub> -VASC score, points   | 3.8 (1.4)       | 3.4 (1.3)           | < 0.001     | 3.4 (1.3)                         | 3.4 (1.4)        | 0.924   |  |  |  |
| HASBLED score, points  | 2.8 (1.1)       | 2.7 (1.1)           | 0.204       | 3.0 (1.2)                         | 2.7 (1.1)        | < 0.001 |  |  |  |
| Antithrombotic therapy   | . ,             |                     |             | , , , , , , , , , , , , , , , , , | · · · · ·        |         |  |  |  |
| Anticoagulation therapy  | 584 (72.9)      | 11,048 (78.3)       | < 0.001     | 1,058 (84.8)                      | 10,574 (77.4)    | < 0.001 |  |  |  |
| Antiplatelet therapy   | 194 (24.2)      | 2,701 (19.1)        | < 0.001     | 220 (17.6)                        | 2,675 (19.6)     | 0.099   |  |  |  |
| 459  |                 | , , , ,             |             | × /                               |                  |         |  |  |  |
|  |                 |                     | D.          |                                   |                  |         |  |  |  |
| 400 AF: Airiai Fibriliation; COPD: Unronic Obstructive Pulmonary Disease; GI: Gastrointestinal; HCM: |                 |                     |             |                                   |                  |         |  |  |  |
| 461 Hypertrophic Cardiomyopa   | thy; LVEF: Left | Ventricular Ejectio | on Fraction | ; MR: Mitral Regurg               | gitation; NSAID: |         |  |  |  |
| 462 Non-Steroidal Anti-Inflammatory Drugs; SD: Standard Deviation.                                   |                 |                     |             |                                   |                  |         |  |  |  |
|  |                 |                     |             |                                   |                  |         |  |  |  |

| 463 | <sup>a</sup> Defined by National Institute on Alcohol Abuse and Alcoholism as consuming $\geq$ 4 alcoholic drinks on any day or $\geq$ 14 alcoholic |
|-----|---|
| 464 | drinks per week for men, or consuming $\geq 3$ alcoholic drinks on any day or $\geq 7$ alcoholic drinks per week for women, in the past             |
| 465 | month.  |
| 466 | <sup>b</sup> Categories of chronic kidney disease according to the National Kidney Foundation classification, using the Chronic Kidney              |
| 467 | Disease Epidemiology Collaboration (CKD-EPI) equation to estimate the glomerular filtrate rate  |
| 468 | <sup>c</sup> Mild liver disease was defined as elevations of aspartate transaminase (AST) and/or alanine transaminase (ALT) more than 3             |

469 times the upper limit of normal. Cirrhosis was defined by clinical, biochemical, and radiological parameters, endoscopic results,
 470 ultrasonography, and/or even histology.

- 471 <sup>d</sup> Anemia was defined According to the World Health Organization as hemoglobin levels < 12.0 g/dL in women and < 13.0 g/dL</li>
   472 in men. Moderate-severe anemia was defined as hemoglobin levels < 10 g/dL.</li>
- 473 <sup>e</sup> Thrombopenia was subdivided into mild (platelet count 100,000 to 150,000/microL) and moderate-severe (<100,000/microL)
- 474 <sup>f</sup> Active cancer was defined according to the last definition proposed by the Scientific and Standardization Committee of the
- 475International Society on Thrombosis and Haemostasis, as cancer diagnosed within the 6 months before the medical evaluation for476AF, cancer with local progression, metastasis, or lack of complete remission in the last 6 months, as well as patients receiving
- 477 specific cancer therapy within the previous 6 months

- 478 <sup>g</sup> Equivalent to moderate-to-severe dementia, defined as cognitive decline between stages 5 and 7 of the Reisberg Global
  - Deterioration Scale, which corresponds to stages of the Functional Assessment Staging scale 5
- 480 <sup>h</sup>Based on a CONUT (Controlling Nutritional status) score 5 points.
- 481

479

482

**Table 2.** Ischemic stroke prediction model and major bleeding prediction model.

| Prodictors of Events                     | Predictor of ischer                      | mic stroke             | Predictor of major bleeding                                |         |  |
|--|--|------------------------|--|---------|--|
| Predictors of Events                     | HR (95% CI)                              | P Value                | HR (95% CI)  | P Value |  |
| Age, per year                            | 1.06 (1.05-1.07)                         | < 0.001                | 1.02 (1.01-1.03)   | < 0.001 |  |
| Female sex                               |  |                        | 0.70 (0.61-0.78)   | < 0.001 |  |
| Cigarette smoker                         |  |                        | 1.40 (1.10-1.79)   | 0.008   |  |
| Alcohol abuse <sup>a</sup>               |  |                        | 1.17 (1.01-1.35)   | 0.036   |  |
| Diabetes mellitus                        |  |                        | 1.21 (1.06-1.39)   | 0.004   |  |
| Prior stroke                             | 1.92 (1.54-2.38)                         | < 0.001                |  |         |  |
| Moderate-severe aortic stenosis          | 1.50 (1.08-2.07)                         | 0.014                  | 1.56 (1.22-1.99)   | < 0.001 |  |
| Moderate-severe MR                       |  |                        | 1.33 (1.02-1.73)   | 0.032   |  |
| HCM                                      | 1.69 (1.01-2.82)                         | 0.044                  |  |         |  |
| CKD <sup>b</sup>                         |  |                        |  |         |  |
| Stage 1                                  |  |                        | Ref  | Ref     |  |
| Stage 2                                  |  |                        | 0.92 (0.77-1.10)   | 0.342   |  |
| Stage 3a                                 |  |                        | 1.04 (0.84-1.30)   | 0.691   |  |
| Stage 3b                                 |  |                        | 1.05 (0.82-1.35)   | 0.702   |  |
| Stage 4                                  |  |                        | 1.47 (1.05-2.04)   | 0.024   |  |
| Stage 5                                  |  |                        | 2.62 (1.59-4.33)   | < 0.001 |  |
| Non cirrhotic Liver disease <sup>c</sup> |  |                        | 1.51 (1.12-2.04)   | 0.007   |  |
| Cirrhosis <sup>c</sup>                   |  |                        | 2.40 (1.65-3.50)   | < 0.001 |  |
| Mild Anemia <sup>d</sup>                 |  |                        | 1.73 (1.48-2.02)   | < 0.001 |  |
| Moderate-severe Anemia <sup>d</sup>      |  |                        | 2.47 (1.88-3.25)   | < 0.001 |  |
| Prior bleeding admission                 |  |                        | 1.55 (1.26-1.91)   | < 0.001 |  |
| Prior GI ulcer                           |  |                        | 1.64 (1.04-2.58)   | 0.034   |  |
| Cognitive impairment <sup>e</sup>        | 1.40 (1.20-1.83)                         | < 0.001                | 1.41 (1.18-1.69)   | < 0.001 |  |
| Malnutrition <sup>f</sup>                |  |                        | 1.30 (1.03-1.63)   | 0.025   |  |
| Permanent AF                             | 1.60 (1.35-1.89)                         | < 0.001                | 1.23 (1.08-1.39)   | 0.001   |  |
| Corticosteroid/NSAID                     |  |                        | 1.23 (1.07-1.42)   | 0.004   |  |
| Anticoagulation                          | 0.70 (0.56-0.86)                         | < 0.001                | 1.64 (1.36-1.99)   | < 0.001 |  |
| Predictive ability of the model          | Harrel C-Index<br>Grønnesby and Borgan I | 0.687<br>P-value=0.116 | Harrel C-Index 0.671<br>Grønnesby and Borgan P-value=0.549 |         |  |

485 AF: Atrial Fibrillation; CKD: Chronic Kidney Disease; GI: Gastrointestinal; HCM: Hypertrophic
486 Cardiomyopathy; HR: Hazard Ratio; MR: Mitral Regurgitation; NSAID: Non-Steroidal Anti-Inflammatory
487 Drugs.

488

489

<sup>a</sup> Defined by National Institute on Alcohol Abuse as consuming  $\geq 4$  alcoholic drinks on any day or  $\geq 14$  alcoholic drinks per week for men, or consuming  $\geq 3$  alcoholic drinks on any day or  $\geq 7$  alcoholic drinks per week for women, in the past month.

- 490 <sup>b</sup> Categories of chronic kidney disease according to the National Kidney Foundation classification, using the Chronic Kidney
   491 Disease Epidemiology Collaboration (CKD-EPI) equation to estimate the glomerular filtrate rate
- 492 <sup>c</sup> Mild liver disease was defined as elevations of aspartate transaminase (AST) and/or alanine transaminase (ALT) more than 3
   493 times the upper limit of normal. Cirrhosis was defined by clinical, biochemical, and radiological parameters, endoscopic results,
   494 ultrasonography, and/or even histology.

- <sup>d</sup> Anemia was defined According to the World Health Organization as hemoglobin levels < 12.0 g/dL in women and < 13.0 g/dL</li>
   in men. Moderate-severe anemia was defined as hemoglobin levels < 10 g/dL.</li>
   <sup>e</sup> Equivalent to moderate-to-severe dementia, defined as cognitive decline between stages 5 and 7 of the Reisberg Global
   Deterioration Scale, which corresponds to stages of the Functional Assessment Staging scale 5
   <sup>f</sup> Based on a CONUT (Controlling Nutritional status) score 5 points.
   FIGURES
- **Figure 1.** Distribution of OAC score among patients of derivation cohort (n = 14,915) with

annual incidence of events according to risk score groups.





520

- 521 Figure 2. Observed rates of embolic (A) and bleeding (B) outcomes during the follow-up by
- 522 OAC score groups in derivation cohort.



540

541

Figure 3. Balance between embolic and bleeding outcomes in anticoagulated and nonanticoagulated patients according to OAC score groups in both derivation and validation
cohorts.



561

562





annual incidence of events according to risk score groups.

582

583

**Figure 5.** Observed rates of embolic (A) and bleeding (B) outcomes during the follow-up by



